Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: PPARγ activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway

Fig. 1

PPARγ is a favorable prognostic factor in patients with bladder cancer. (a) Expression of PPARγ in para-cancer (normal) and cancer tissues determined with immunohistochemistry staining. (b) PPARγ expression was lower in cancer tissues. (c) Different levels of PPARγ expression in bladder cancer cases determined with immunohistochemistry staining. (d) Overall survival analysis in bladder cancer cohort (n = 66). (e) Transcriptional alteration of PPARG mRNA determined by RNA-sequencing in TCGA MIBC cases. (f) Correlation of PPARG expression with linear copy-number. (d) Overall survival analysis on PPARG alteration in TCGA cohort (n = 412)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us